- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07399678
Studie van ALV-100 om de veiligheid, verdraagbaarheid en PK/PD te beoordelen bij deelnemers met overgewicht/obesitas met of zonder T2D
Een fase 1b, gerandomiseerde, dubbelblinde, placebo-gecontroleerde, dosis-escalatiestudie naar de veiligheid, verdraagbaarheid, farmacokinetiek en farmacodynamiek van ALV-100 bij deelnemers met overgewicht of obesitas met of zonder diabetes type 2
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33172
- Clinical Pharmacology of Miami
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43212
- Ohio Clinical Trials
-
-
Texas
-
San Antonio, Texas, Verenigde Staten, 78240
- Endeavor Clinical Trials
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
For Part A and B
- Adult male and female participants, aged 18 to 65 years, inclusive, at the time of signing the informed consent form
- Body mass index between 27.0 to 39.9 kg/m2 at Screening, both inclusive; overweight should be due to excess adipose tissue, as judged by the Investigator.
- Have a stable body weight (< 5.0 kg/11 lbs self-reported change) within 90 days prior to Screening
- Females must be surgically sterile (by means of bilateral salpingectomy, hysterectomy or bilateral oophorectomy) or be post-menopausal (defined as spontaneous cessation of menses for at least 1 year prior to Screening). Females who are post-menopausal and < 55 years must have a follicle-stimulating hormone level > 40 IU/L at Screening.
- Males with female partners of child-bearing potential must be willing to practice abstinence or must agree to use condom as contraception throughout the duration of the study. This criterion may be waived for male participants who have had a documented successful vasectomy > 6 months before signing the ICF.
For Part B only
- Diagnosis of Type 2 Diabetes for at least 180 days prior to Screening.
- Glycemic control managed by diet and exercise alone or by stable treatment with metformin and/or sodium-glucose cotransporter 2 inhibitors (SGLT-2i), with no dose changes within 3 months prior to Screening.
- Hemoglobin A1c (HbA1c) between 6.5 % and 9.0% (equivalent to 48-75 mmol/mol), both inclusive, at Screening.
Exclusion Criteria:
For Part A and B
- History or presence of any clinically relevant respiratory, metabolic (including dyslipidemia, however screening total cholesterol below or equal to 302 mg/dL (7.8 mmol/L) and/or screening triglyceride below or equal to 500 mg/dL (5.65 mmol/L) is accepted), renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with type 2 diabetes in Part B) at the discretion of the Investigator.
- Participants with a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 or a personal history of nonfamilial medullary thyroid carcinoma.
- Current or history of chronic or acute pancreatitis.
- Obesity caused by known endocrinologic disorders (e.g., Cushing syndrome) or monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndrome).
- History of major depressive disorder or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or anxiety disorder).
- Lifetime history of a suicide attempt or of any suicidal behavior by endorsement of (answered yes to) any of the items in the suicidal behavior section on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening.
- Systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at Screening.
- History of or current cardiovascular disease, including but not limited to stable and unstable angina, myocardial infarction, congestive heart failure, transient ischemic attack, stroke, clinically significant arrhythmias and conduction disorders or venous thromboembolism.
Part A only
• History or clinical evidence of Type 1 or Type 2 diabetes mellitus, including HbA1c ≥ 6.5% and/or a fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) at Screening (female participants with a history of gestational diabetes are allowed).
Part B only
- Fasting plasma glucose (FPG) > 270 mg/dL (15.0 mmol/L) at Screening.
- Proliferative retinopathy or maculopathy as judged by the investigator based on a recent (within1.5 years from Screening) ophthalmologic examination.
- Severe neuropathy as judged by the investigator.
- Advanced nephropathy (defined as albuminuria ≥ 300 mg/g).
- History of severe hypoglycemia or hypoglycemic unawareness as judged by the investigator.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part A - Cohort 1 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Placebo-vergelijker: Part A - Cohort 1 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
Experimenteel: Part A - Cohort 2 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Placebo-vergelijker: Part A - Cohort 2 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
Experimenteel: Part A - Cohort 3 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Placebo-vergelijker: Part A - Cohort 3 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
Experimenteel: Part A - Cohort 4 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Placebo-vergelijker: Part A - Cohort 4 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
Experimenteel: Part B - T2D Cohort (ALV-100)
Participants with overweight or obesity with type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
Placebo-vergelijker: Part B - T2D Cohort (Placebo)
Participants with overweight or obesity with type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Safety and tolerability
Tijdsspanne: From First Dose to Week 52
|
Incidence of treatment emergent adverse events (TEAEs) |
From First Dose to Week 52
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pharmacokinetics (PK) of intact ALV-100 and total ALV-100 - Cmax, MD
Tijdsspanne: From First Dose to Week 52
|
Maximum observed serum concentration after multiple doses (MD) (Cmax, MD) |
From First Dose to Week 52
|
|
Pharmacokinetics (PK) of intact ALV-100 and total ALV-100 - AUC(0-τ), MD
Tijdsspanne: From First Dose to Week 52
|
Area under the serum concentration-time curve from time zero to τ, where τ is the dosing interval, (AUC(0-τ), MD) |
From First Dose to Week 52
|
|
Pharmacodynamic (PD) impact on body weight
Tijdsspanne: Baseline, Week 32 and Week 52
|
Change from baseline in body weight |
Baseline, Week 32 and Week 52
|
|
Pharmacodynamic (PD) impact on body weight percentage
Tijdsspanne: Baseline, Week 32 and Week 52
|
Change from baseline in body weight percentage |
Baseline, Week 32 and Week 52
|
|
Immunogenicity
Tijdsspanne: From Baseline to Week 52
|
Incidence of Anti-ALV-100 drug antibodies, including assessments of cross-reactivity and neutralizing antibodies. |
From Baseline to Week 52
|
|
Relationship between ALV-100 serum concentration and QTc interval changes (Part A Only)
Tijdsspanne: From First Dose to Week 52
|
Measurement of change in individual specific heart rate corrected QT interval (QTcI) and Fridericia heart rate corrected QT interval (QTcF) on 12-lead ECG. |
From First Dose to Week 52
|
|
Paracetamol (acetaminophen) absorption test (PAT) (Part A Only)
Tijdsspanne: From First Dose to Week 52
|
Measurement of acetaminophen PK parameters to evaluate the effect of ALV-100 on the gastric emptying rate. |
From First Dose to Week 52
|
|
Pharmacodynamic (PD) impact of ALV-100 on antidiabetic medication (Part B Only)
Tijdsspanne: From Baseline to Week 32
|
Change in use of concomitant glucose-lowering medication |
From Baseline to Week 32
|
|
Pharmacodynamic (PD) impact of ALV-100 on glycemic parameters (Part B Only)
Tijdsspanne: Week 32 and Week 52
|
Measuring the number of participants achieving target Hemoglobin A1c values |
Week 32 and Week 52
|
|
Hypoglycemic Safety (Part B Only)
Tijdsspanne: From Baseline to Week 52
|
Measured by the incidence of symptomatic hypoglycemia, documented symptomatic hypoglycemia and severe hypoglycemia |
From Baseline to Week 52
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Karen Tornøe, MD, PhD, Alveus Therapeutics
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Endocriene systeemziekten
- Voedingsstoornissen
- Metabole ziekten
- Overvoeding
- Lichaamsgewicht
- Veranderingen in lichaamsgewicht
- Glucosemetabolismestoornissen
- Suikerziekte
- Pathologische aandoeningen, tekenen en symptomen
- Voedings- en stofwisselingsziekten
- Tekenen en symptomen
- Overgewicht
- Obesitas
- Gewichtsverlies
- Diabetes mellitus, type 2
Andere studie-ID-nummers
- ALV-102-1
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .